Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Other Non-Current Assets (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Other Non-Current Assets for 7 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 25.45% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, down 25.45%, and an annual FY2025 reading of $2.2 million, down 25.45% over the prior year.
  • Other Non-Current Assets was $2.2 million for Q4 2025 at aTYR PHARMA, down from $2.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.5 million in Q4 2023 and bottomed at $66000.0 in Q1 2025.
  • Average Other Non-Current Assets over 5 years is $2.2 million, with a median of $2.9 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets soared 1317.09% in 2022, then crashed 97.95% in 2025.
  • Year by year, Other Non-Current Assets stood at $158000.0 in 2021, then skyrocketed by 1903.16% to $3.2 million in 2022, then rose by 10.08% to $3.5 million in 2023, then dropped by 15.3% to $3.0 million in 2024, then fell by 25.45% to $2.2 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ATYR at $2.2 million in Q4 2025, $2.7 million in Q3 2025, and $2.9 million in Q2 2025.